Biotech | October 27, 2025
Novartis to acquire Avidity Biosciences for $12 billion
The acquisition will follow the planned separation of Avidity’s early-stage precision cardiology programs into a new, independent company
The acquisition will follow the planned separation of Avidity’s early-stage precision cardiology programs into a new, independent company
Bioconjugation capability to complement commercial payload, linker, and monoclonal antibody services
INEOS production of BDO in Germany, which produces a vital ingredient for antibiotics, statins and vitamin B6, is being crushed by a flood of carbon heavy imports and product dumping from the Far East
Nicardipine Hydrochloride in 0.9% Sodium Chloride Injection is indicated for the short-term treatment of hypertension when oral therapy is not feasible or desirable
The product is indicated for the chronic management of patients with Urea Cycle Disorders
Takeda will make an upfront payment of $1.2 billion, which includes a $100 million equity investment in Innovent
XTANDI is the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in this patient population, supporting its earlier use in this setting
Expanding US operations to address the increased demand for API development and manufacturing
Triamcinolone Acetonide injectable suspension USP is indicated for various autoimmune, inflammatory, and other conditions
Medroxyprogesterone acetate-SC is a three-month contraceptive that can be administered by healthcare workers or self-injected after appropriate training
Subscribe To Our Newsletter & Stay Updated
